SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news

 

 

After doubling in size, LabConnect secures $24.5m investment

Melissa Fassbender

By Melissa Fassbender

14-Jun-2017

LabConnect provides central laboratory and scientific support services to biopharmaceutical companies. (Image: iStock/uris)
LabConnect provides central laboratory and scientific support services to biopharmaceutical companies. (Image: iStock/uris)

The global central laboratory and support services provider has secured a $24.5m Series A investment and is on track to double in size, again, over the next five years, says CEO.

The investment, LabConnect’s first institutional equity funding, comes from ABS Capital Partners, Pablo Capital, and BroadOak Capital.

We’ve doubled in size over the last three years and expect another doubling within the next five years and are on track to do so,” Eric Hayashi, president and CEO of LabConnect, told Outsourcing-Pharma.com.

Hayishi attributes the company’s success to its expertise in managing complex laboratory projects, including sample tracking, biorepository, PBMC processing, data integration from multiple laboratories, and functional outsourcing support for functions such as analytical test transfer.

The funding will support various growth initiatives, including enhancements to the company’s proprietary technology platform and services, Hayishi said. Additionally, he explained it will provide liquidity to LabConnect’s early shareholders.

Partnering with this group of experienced laboratory services investors will enable us to remain well-positioned to continue our strong growth and to accommodate the ever-changing complexity of clinical studies for our customers,” Hayishi added.

Related products

Related suppliers

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...